Clinical Trial Update: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema [Phase 3]

View source ↗

Summary

A Phase 3 safety and pharmacokinetic study of CSL312_3003 in children aged 2 to 11 with hereditary angioedema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• CSL312_3003

Snippet

Sponsor: CSL Behring | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED